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Abstract
Background: Astrocytes, which play an active role in chronic inflammatory diseases like multiple sclerosis, exist
close to mast cells with which they share perivascular localization. We previously demonstrated the possibility that
astrocytes and mast cells interact in vitro and in vivo. This study aimed to investigate the signaling pathways and
the role for astrocytes in the interaction of astrocytes and mast cells.
Methods: We co-cultured human U87 glioblastoma (U87) and human mast cell-1 (HMC-1) cell lines, and mouse
cerebral cortices-derived astrocytes and mouse bone marrow-derived mast cells (BMMCs). Intracellular Ca
2+ ([Ca
2+]i)
was measured by confocal microscopy; CD40 siRNA by Silencer Express Kit; small GTPases by GTP-pull down assay;
PKCs, MAPKs, CD40, CD40L, Jak1/2, STAT1, TNF receptor 1 (TNFR1) by Western blot; NF-B and AP-1 by EMSA;
cytokines by RT-PCR. An experimental allergic encephalomyelitis (EAE) model was induced using myelin
oligodendrocyte glycoprotein (MOG) peptide and pertussis toxin in mice. Co-localization of TNFR1 and astrocytes
in EAE brain tissues was determined by immunohistochemistry.
Results: Each astrocyte co-culture had increases in [Ca
2+]i levels, release of cytokines and chemokines; activities of
Rho-family GTPases, NF-B/AP-1/STAT1
727, and Jack1/2, STAT1
701. These effects were inhibited by anti-CD40
antibody or CD40 siRNA, and signaling pathways for Jak1/2 were inhibited by anti-TNFR1 antibody. EAE score,
expression of TNFR1, and co-localization of TNFR1 and astrocytes were enhanced in brain of the EAE model. Anti-
CD40 antibody or 8-oxo-dG pretreatment reduced these effects in EAE model.
Conclusions: These data suggest that astrocytes activated by the CD40-CD40L interaction in co-culture induce
inflammatory cytokine production via small GTPases, and the secreted cytokines re-activate astrocytes via Jak/
STAT1
701 pathways, and then release more cytokines that contribute to exacerbating the development of EAE.
These findings imply that the pro-inflammatory mediators produced by cell-to-cell cross-talk via interaction of
CD40-CD40L may be as a promising therapeutic target for neurodegenerative diseases like MS.
Background
Astrocytes, which are known as a major glial cell type,
have important physiological properties in central nerve
system (CNS) homeostasis. Astrocytes have a dynamic
role in regulating neuronal function [1], and play an
active and dual role in CNS inflammatory diseases such
as multiple sclerosis (MS) [2].
MS is a progressive and neurodegenerative disease of
the CNS. A major pathological hallmark of MS is the
presence of demyelinated lesions [3,4]. In the active
phase of this disease, which is known to be caused in the
recruitment and activation of various cell types such as T
cells [5], macrophages and dendritic cells [6] etc., mast
cells [6,7] and astrocytes [8] have been reported as an
effector cells, although these cells remain to be further
determined. An accumulation of mast cells in MS pla-
ques and normal appearing white matter observed by his-
topathological analysis [9,10], an elevation of mast cell
specific enzyme (tryptase) in the cerebrospinal fluid
(CSF) of MS patients [11], and an increase of mast cell
markers (FcεRI, tryptase and chymase) [12] show the
implication of mast cells in the pathophysiology of MS.
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encephalomyelitis (EAE) in monkey [13,14] and mice
[15-19] as an animal model of MS were previously
reported by others and our laboratories. However, it has
been reported that mast cells are dispensable for develop-
ment of disease [20], although they accumulate in the
brain and CNS [18,19,21] and the reconstitution of mast
cell population in W/W(v) mice, which are deficient in
c-kit receptor, restores induction of early and severe
disease to wild-type levels [19].
Astrocytes participate in immune function through the
specific loss of a cytokine receptor like gp130, or through
reduction of nuclear factor-B( N F - B) signaling [22].
Astrocytes lead to chronic inflammation and progressive
neurodegeneration by overexpression of several cytokines
such as interleukin (IL)-1b, tumor necrosis factor (TNF)-
a,i n t e r f e r o n( I F N ) - g, IL-6, IL-12, and transforming
growth factor (TGF)-b [23,24], and by overexpression of
chemokine like CCL2 (MCP-1) [25]. The cytokine TNF-
a is also an important factor in the regulation of neuro-
nal apoptotic cell death. TNF-a mRNA expression in
blood mononuclear cells is correlated with disease activ-
ity in relapsing-remitting MS [26], while high IL-6 levels
in the CNS [27] and TNF-a release in astrocytes [28] are
correlated with the development of EAE in rats. Thus,
future challenges include determining how individual
cytokines and chemokines produced by astrocytes influ-
ence the development of inflammation and the behavior
of infiltrating immune cell populations.
In the CNS, the co-stimulatory molecule CD40 is
expressed in a variety of cells including astrocytes and
microglia, and the natural ligand of CD40 (CD40L)
belongs to the TNFR superfamily [29]. Interaction of
CD40 on astrocytes and CD40L on the infiltrating T cells
and other resident CNS cells such as monocytic cells,
natural killer cells and mast cells, trigger a series of intra-
cellular signaling events that promote the production of a
wide array of cytokines, chemokines and neurotoxins
[30]. In the mouse [31] and monkey [32] EAE, treatment
with anti-CD40 antibody prevented disease development
and reduced clinical signs.
We previously demonstrated that mast cells co-
cultured with astrocytes are activated by CD40-CD40L
interaction, and the activated mast cells induce release of
mediators that participate in pathophysiology of chronic
neurodegenerative diseases like MS [18]. However, the
role of astrocytes activated in the co-culture is not yet
clarified. Therefore, we hypothesized that both cells are
bi-directionally activated in vitro and in vivo, and exam-
ined the signaling pathways and role for astrocytes in the
co-culture system and EAE model. We observed that
cross-talk between astrocytes and mast cells through
CD40-CD40L produces inflammatory cytokines by Rho-
family GTPases, and the produced cytokines re-activate





U87 glioblastoma cell lines were obtained from Korea Cell
Line Bank (Seoul, Korea) and grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM) (Gibco, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum (FBS; Welgene,
Daegu, Korea), 10 U/ml penicillin and 10 μg/ml strepto-
mycin (Gibco, Carlsbad, CA) at 37°C in a 5% CO2
atmosphere.
HMC-1 cells (human mast cell line) were kindly pro-
vided by Dr. J. H. Butterfield (Mayo Clinic, Rochester,
MN). Cells were cultured in Iscoves modified Dulbecco’s
medium (IMDM; Gibco, Carlsbad, CA) containing 10%
FBS at 37°C in a 5% CO2 atmosphere. These culture
conditions were designated as control medium.
Preparation of primary brain astrocytes and bone
marrow-derived mast cells (BMMCs)
Primary brain astrocytes were isolated from the cerebral
cortices of 1 day-old BALB/c mice as previously described
[ 1 8 ] .I nb r i e f ,a n i m a l sw e r es a crificed by decapitation,
meninges were removed, and cortices were minced and
gently dissociated in Hank’s balanced salt solution (HBSS;
Sigma-Aldrich, St. Louis, MO). Cells were supplemented
with DMEM containing 5% FBS, transferred into 75 cm
2
culture flasks (5 × 10
10 cells/flask), and incubated at 37°C
in a humidified atmosphere of 95% air, 5% CO2. After 14
days of culturing, floating microglia was removed by shak-
ing the flask vigorously. More than 95% of cells were
stained for astrocyte specific glial fibrillary acidic protein
(GFAP; Sigma-Aldrich, St. Louis, MO).
Bone marrow cells were flushed from femurs and tibias
of BALB/c mice (female, 8 weeks old) as described pre-
viously [18]. Briefly, red blood cells were lysed using
0.1 M NH4Cl, and the remaining cells were washed,
resuspended, and cultured for 5 weeks in RPMI-1640
(Gibco, Carlsbad, CA) supplemented with 10% FBS and
50% WEHI-3B conditioned media which contained IL-3.
BMMCs (5 × 10
4 cells) were collected onto object glasses
by cytospin (400 × g, 3 min). Cells were fixed in metha-
nol for 2-3 min, and then stained with May Grünwald
solution for 15 min followed by Giemsa solution for 10
min and by washing with H2O, and then BMMCs were
confirmed under microscope. Purity of BMMCs was
more than 95% of total cells.
Co-culture of astrocytes and mast cells
U87 cells or primary brain astrocytes (3 × 10
6 cells)
w e r eg r o w ni n7 5c m
2 flasks until confluent, and then
HMC-1 cells or BMMC (1 × 10
6 cells), respectively,
were added to each astrocyte flask because mast cells
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24 h. In vivo, brain astrocytes outnumber mast cells, and
we chose a 3:1 ratio of mast cells and astrocytes to acti-
vate astrocytes. After co-culture, mast cells were sepa-
rated from astrocytes attached to the flask by gentle
shaking. Astrocytes were separated from flasks using
trypsin treatment and harvested by centrifugation
(800 × g; referred to co-cultured-U87 cells or co-cul-
tured-primary astrocytes). The optimal concentration
and time for anti-CD40 antibody treatment, 8-oxo-dG
pretreatment or anti-TNFR1 antibody treatment were
300 ng/ml for 1 h, 300 μg/ml for 10 min, 300 ng/ml for
30 min, respectively, obtained in preliminary experiments.
For inhibition experiments, U87 cells (1 × 10
6 cells)
were pre-incubated for 1 h, and Jak inhibitor (10 μM
AG490), PKC inhibitors (5 nM staurosporine and
Gö6976), MAP kinase inhibitors (50 μM PD98059 for
ERK, 10 μM SP600125 for JNK, and 10 μM SB203580 for
p38) or Ca
2+ influx inhibitor 2-aminoethoxydiphenyl
borate (100 μM 2-APB) were pretreated in astrocytes 5,
10 and 10 min, respectively, before initiating co-culture.
Measurement of intracellular [Ca
2+]i levels
Co-cultured-U87 cells or -primary astrocytes (1 × 10
6
cells) were seeded on cover slides, and each slide was
then incubated for 30 min with Fluo-3 AM (5 μM)
(Sigma-Aldrich, St. Louis, MO). The intracellular cal-
cium ([Ca
2+]i) levels in co-cultured-astrocytes were ana-
lyzed using LSM 510 laser scanning microscopy (Carl
Zeiss, oberkochen, Germany) [18]. Intensity for [Ca
2+]i
level indicated the ratio of control intensity (intensity of
control fluorescence = 1).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Expression of cytokines or chemokines (IL-1b, IL-6, TNF-
a, MCP-1, RANTES, and IP-10) were analyzed by RT-
PCR. Total cellular RNA was isolated from the co-
cultured-astrocytes (3 × 10
6 cells) using Trizol reagent
(Molecular Research Center Inc., Cincinnati, OH). RT-
PCR was performed in a final volume of 50 μlu s i n ga
amfiRivert 1-step RT-PCR kit (GenDEPOT, Barker, TX)
in an automated thermal cycler (BIOER Technology Co.,
Hangzhou, China). PCR assays were performed for
35 cycles. Each cycle consisted of the following steps:
denaturation at 94°C for 30 seconds, annealing at 56°C for
45 seconds, and extension at 72°C for 1 min. PCR products
were analyzed using a 1% agarose gel containing ethidium
bromide (EtBr; Sigma-Aldrich, St. Louis, MO) [18].
The primer sequences used were as follows: human
IL-1b sense, 5’-AAG GAG AAC CAA GCA ACG ACA
AAA-3’; anti-sense, 5’-CCT GTA TGC CTC TGG TCG
TA-3’, mouse IL-1b sense, 5’-TGA AGG GCT GCT TCC
AAA CCT TTG ACC-3’; anti-sense, 5’-TGT CCA TTG
AGG TGG AGA GCT TTC AGG-3’, human IL-6 sense,
5’-GCC TTC GGT CCA GTT GCC TT-3’; anti-sense,
5’-GCA GAA TGA GAT GAG TTG TC-3’,m o u s eI L - 6
sense, 5’-TGG AGT CAC AGA AGG AGT GGC TAA
G-3’;a n t i - s e n s e ,5 ’-TCT GAC CAC AGT GAG GAA
TGT CCA C-3’, human TNF-a sense, 5’-TGA GCA
CTG AAA GCA TGA TC-3’; anti-sense, 5’-TTA TCT
C T CA G CT C CA C GC C - 3 ’, mouse TNF-a sense,
5’-TTC TGT CCC TTT CAC TCA CTG G-3’;a n t i -
sense, 5’-TTG GTG GTT TGC TAC GAC GTG G-3’,
human MCP-1 sense, 5’-CCC TTC TGT GCC TGC
TGC TCA-3’; anti-sense, 5’-CTG TTC GTT TGG GTT
TGA GGC TT-3’, mouse MCP-1 sense, 5’-GAA GGA
ATG GGT CCA GAC AT-3’; anti-sense, 5’-ACG GGT
CAA CTT CAC ATT CA-3’, human RANTES sense, 5’-
C C TC G CT G TC A TC C TC A TT G CT - 3 ’; anti-sense,
5’-TAC TCC CGA ACC CAT TTC TTC TC-3’,m o u s e
RANTES sense, 5’-GAT GGA CAT AGA GGA CAC
AAC T-3’; anti-sense, 5’-TGG GAC GGC AGA TCT
GAG GG-3’,h u m a nI P - 1 0s e n s e ,5 ’-ATC AAA CTG
CGA TTC TGA TTT GCT GCC TTA-3’;a n t i - s e n s e ,
5’-TGG CCT TCG ATT CTG GAT AG-3’, mouse IP-10
sense, 5’-ACC ATG AAC CCA AGT GCT GCC GTC-3’;
anti-sense, 5’- GCT TCA CTC CAG TTA AGG AGC
CCT-3’, human GAPDH sense, 5’-GTG AAG GTC GGT
AAC GG-3’;a n t i - s e n s e ,5 ’-GAT GCA GGG ATG ATG
TTC TG-3’, mouse GAPDH sense, 5’-AAC TTT GGC
ATT GTG GAA GG-3’;a n t i - s e n s e ,5 ’-ACA CAT TGG
GGG TAG GAA CA-3’.
CD40 siRNA transfection
CD40 small interfering RNA (siRNA)-expressing vectors
were generated using the Silencer Express Kit (Ambion
Inc., Austin, TX). Sense (ACA CTA CAC AAA TGT
TCC ACT GGG CTG AGA ACC GGT GTT TCG TCC
TTT CCA CAA G) and anti-sense (CGG CGA AGC
TTT TTC CAA AAA ATT CTC AGC CCA GTG GAA
CAC TAC ACA AAT G) hairpin siRNA template oligo-
nucleotides, specific for CD40 mRNA, were used [18].
Transfection was performed according to the manu-
facture’s method. Briefly, 1 μg of vector expressing
CD40 siRNA or control siRNA was incubated with 50
μl of serum-free media for 5 min (Solution A), and 2 μl
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was
incubated with serum-free media for 5 min (Solution B).
Solution A was mixed with Solution B, and incubated
for 20 min. After incubation, U87 cells were added to
the mixture. The expression of CD40 after CD40 siRNA
transfection was performed using western blot. Next,
transfected-U87 cells were co-cultured with HMC-1
cells for various times. After co-culture, the [Ca
2+]i
levels, Rho families, PKC isoforms and MAP kinases
were analyzed using a LSM 510 laser scanning micro-
scopy, GST effector pull-down assay, Western blot, and
EMSA, respectively.
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Small GTPase protein activities were assayed as pre-
viously described [18] using EZ-DetectTM protein Acti-
vation kits (Upstate Biotechnology, Lake Placid, NY).
Co-cultured-astrocytes (1 × 10
7 cells) were suspended in
0.5 ml of a lysis buffer [25 mM Tris-HCl (pH 7.5),
1 5 0m MN a C l ,5m MM g C l 2, 1% NP-40, 1 mM DTT,
5 %g l y c e r o l ,1m MP M S F ,1μg/ml aprotinin, 1 μg/ml
leupeptin (Roche Molecular Biochemicals, Mannheim
Germany)] for 30 min on ice, and supernatants were
obtained by centrifugation (13,000 × g for 20 min). The
active form of small GTPase proteins were obtained
according to the manufacturer’s protocol from the
supernatants by affinity precipitation using Pak-1 pro-
tein binding domain (PBD), which was fused to GST
(glutathione-S-transferase) ,a n dv i s u a l i z e db yW e s t e r n
blot analysis with anti-rabbit Rac1/2, cdc42 (1:1,000;
PIERCE, Rockford, IL).
Western blot analysis
Co-cultured-U87 cells, -primary astrocytes (3 × 10
6 cells/
50 μl) or EAE brain tissues (50 mg) were homogenized in
lysis buffer [10 mM HEPES (pH 7.9), 10 mM KCl,
0 . 1m ME D T A ,0 . 1m ME G T A ,1m MD T T ,0 . 5m M
PMSF, 2.0 μg/ml aprotinin, 2.0 μg/ml leupeptin],
and allowed to swell on ice for 30 min. Cell lysates
(μg) were subjected to 8-10% sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (PAGE) and
transferred to nitrocellulose membranes (Amersham
Biosciences, Buckinghamshire, UK). Membranes were
washed with phosphate-buffered saline (PBS; Gibco,
Carlsbad, CA) containing 0.1% Tween 20 (PBST), and
then blocked for 1 h in PBST containing 5% skim milk
(BD Bioscience, Sparks, MD). After washing the mem-
branes with PBST, the membranes were treated with
antibodies against actin, CD40, CD40L, PKC isoforms,
ERK, JNK, p38, Jak1/2, STAT1, CBP and TNFR1 (Santa
Cruz Biotechnology, Santa Cruz, CA), and then mem-
branes were treated with p-PKC isoforms, p-ERK, p-JNK,
p-p38, p-JAK1/2, p-ser727 STAT1, p-Tyr (Cell Signaling,
Beverly, MA) diluted in PBST (1:1,000), and incubated
for 60 min at room temperature. Membranes were
washed with PBST, and treated with HRP-conjugated
goat anti-mouse or HRP-conjugated rabbit anti-goat IgG
(diluted to 1:5,000~1:10,000; Zymed Laboratory Inc. San
Francisco, CA) in PBST for 60 min. After washing, the
protein bands were visualized using electrogenerated
chemiluminescent (ECL) solution (Amersham Bios-
ciences, Buckinghamshire, UK) [18].
Electrophoretic mobility shift assay (EMSA)
EMSA was performed with
32P-labed probes and 2 μgo f
nuclear extract in 40 μL of EMSA reaction buffer [18].
To perform the competition assay, a 100-fold excess of
unlabeled competitor primer was added to the EMSA
reaction mixture. Nuclear extracts were prepared from
co-cultured cells (1 × 10
6 cells). Cells were washed
twice with ice-cold PBS, and resuspended in 1 ml ice-
cold buffer A [10 mM HEPES/KOH (pH 7.9), 10 mM
KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.2 mM PMSF,
1 μg/ml leupeptin, and 1 μg/ml aprotinin]. After incuba-
tion on ice for 15 min, the cells were lysed by adding
Nonidet P40 (10 μl 10% Nonidet P40, to a final concen-
tration of 0.625%, v/v) and immediately vortexed for
10 sec. Nuclei were harvested by centrifugation at
20,000 × g for 1 min and resuspended in 40 μl ice-cold
buffer C [20 mM HEPES/KOH (pH 7.9), 0.42 M NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 25% gly-
cerol, 0.2 mM PMSF, 1 μg/ml leupeptin, and 1 μg/ml
aprotinin]. After incubation at 4°C for 20 min on a
shaking platform, the nuclei were clarified by centrifuga-
tion at 15,000 × g for 10 min. The supernatant (nuclear
extract) was then transferred to a new tube, and quanti-
fied using Bradford’s method.
The 10 μlo fam i x t u r eo fN F - B( 5 ’-AGT TGA GGG
GAC TTT CCC AGG C-3’,3 ’-TCA ACT CCC CTG
AAA GGG TCC G-5’) or AP-1 (5’-CGC TTG ATG AGT
CAG CCG GAA-3’,3 ’-GCG AAC TAC TCA GTC GGC
CTT-5’) oligonucleotide (1.75 pmol/μl; Promega Cor-
poration, Madison, WI), T4 polynucleotide kinase 10 ×
buffer, [a-
32P]ATP (10 μCi; 3,000 Ci/mmol; PerkinElmer,
Waltham, MA), nuclear-free water, and T4 polynucleo-
tide kinase (5~10 U/μl; Promega Corporation, Madison,
WI) were incubated for 30 min at 37°C. The reaction was
stopped by adding 1 μl EDTA (0.5 M). After adding 89 μl
Tris-EDTA (TE) buffer [10 mM Tris-HCl (pH 8.0), and
1 mM EDTA], unincorporated nucleotides were removed
from the DNA probe by chromatography through a G-25
spin column (Amersham Biosciences, Bucking-hamshire,
UK). The nuclear extract and gel shift binding 5× buffer
[20% glycerol, 5 mM MgCl2,2 . 5m ME D T A ,2 . 5m M
DTT, 250 mM NaCl, 50 mM Tris-HCl (pH 7.5), and 0.25
mg/ml poly (dI-dC) (Roche Molecular Biochemicals,
Mannheim, Germany)] were incubated at room tempera-
ture for 10 min. Next, 20-30 fmol of
32P-labeled NF-B
oligonucleotide was added, and the solution was incu-
bated at room temperature for 20 min. After incubation,
1 μl of 10 × gel loading buffer was added to each reac-
tion. Reaction mixtures were electrophoresed on 6%
polyacrylamide gels, and gels were analyzed using FLA-
2000 (FUJIFILM, Tokyo, Japan).
Immunoprecipitation (IP) for STAT1 on tyrosine 701
phosphorylation
IP before the determination of phosphorylation of STAT1
on tyrosine 701 using immunoblotting was performed
according to method previously described [33]. Agarose
conjugate (50 ml) was washed twice with washing buffer
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room temperature, and then resuspended in washing buf-
fer. Agarose conjugate was added to 10 μl of anti-STAT1
antibody, incubated for 60 min at room temperature with
gentle mixing, and then centrifuged at 3,000 × g for
2 min at 4°C. Samples were washed with 1 ml washing
buffer, and centrifuged at 3,000 × g for 2 min at 4°C; this
step was repeated at least twice. Co-cultured cell lysates
(200 μg of protein) were added to agarose conjugate-
bound antibody, and incubated overnight at 4°C with
gentle mixing. Immunoprecipitated complexes were
washed with washing buffer, and centrifuged at 3,000 × g
for 2 min at 4°C. Pellets were washed with 1 ml washing
buffer, and centrifuged at 3,000 × g for 2 min at 4°C.
This step was repeated at least three times. The pellet
was resuspended in 25-100 μl Laemmli sample buffer
[0.125 M Tris HCl (pH 6.8), 4% SDS, 20% glycerol, 10%
2-mercaptoethanol, 0.004% bromophenol blue]. Samples
were heated at 95°C for 5 min, centrifuged, and the
supernatants were collected (IP sample). Samples were
run on SDS-PAGE, transferred to nitrocellulose, and
immunoblotting was performed.
Induction of EAE
Female mice (C57BL/6, 8 weeks old) were purchased
from Samtako BioKorea (Osan, Korea) and maintained
in specific pathogen-free conditions before sacrifice. All
mice were housed in accordance with guidelines from
the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC), and all protocols
were approved by the Institutional Review Board and
conducted in the Laboratory Animal Research Center of
Sungkyunkwan University.
The EAE model was induced by a method described
previously [18]. Mice (8 mice/group) were divided into
five groups: control, mice injected with CFA alone; EAE,
mice received a subcutaneous injection of 150 μgm y e l i n
oligodendrocyte glycoprotein peptide 35-55 (MOG 35-55;
Sigma, St. Louis, MO) in 100 μl PBS mixed with 100 μlo f
C F A( S i g m a ,S t .L o u i s ,M O ) ;t h r e et r e a t e dg r o u p s ,m i c e
pretreated by intraperitoneal (i.p.) injection of anti-CD40
antibody (1 mg/kg), 8-oxo-dG (60 mg/kg), and a combina-
tion of both for 5 days after MOG injection, respectively.
After MOG injection, each animal received an i.p. injec-
tion of 200 ng pertussis toxin (Invitrogen Life Technolo-
gies, Carlsbad, CA) in 200 μl PBS. The mice were weighed
and scored daily in a blinded fashion by two examiners
according to the following scale: score 0, no disease; score
1, loss of weight and tail weakness; score 2, weakness in
hind limb; score 3, complete hind limb paralysis; score 4,
hind limb paralysis with forelimb weakness or paralysis;
and score 5, moribund or deceased. The concentration of
anti-CD40 antibody (1 mg/kg) and 8-oxo-dG (60 mg/kg)
was injected the same amount used in our previous
experiments [18,34].
Thirty-two days after starting injection, the EAE score
was about 3.8 ± 0.21, and brains were isolated, and
inflammatory cells infiltrated into brain tissues were
determined using hematoxilin and eosin (H&E) [18]. In
general, EAE score reached peak on day 21- 25, but our
EAE score reached peak on day 31- 32 despite the same
method used in other laboratories [15,17]. This difference
may be due to environmental factors. Brain tissues were
fixed in 4% paraformaldehyde, embedded in paraffin, and
cut into 3 μm sections. Brain sections were deparaffinized
with xylene and washed using various percentages of
ethanol. Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide in methanol for 5 min. Slides
were then blocked with 1% BSA in PBS for 1 h. For
immunohistochemistry, a polyclonal primary antibody
against c-kit, GFAP, TNFR1 (Santa Cruz Biotechnology,
Santa Cruz, CA; 1/50 dilution) was applied and the slides
w e r ei n c u b a t e da t4 ° Cf o r2 4h .A f t e rw a s h i n gi nP B S ,
slides were treated with biotinylated secondary antibody
for 10 min, streptoavidin-HRP for 10 min, and chromo-
gen substrate (DakoCytomation, Carpinteria, CA) for
5-10 min. For immunofluorescence, a polyclonal primary
antibody against c-kit or GFAP was then applied and the
slides were incubated at 4°C for overnight. After washing
in PBS, slides were treated with the corresponding FITC
or TEXAS-Red conjugated anti-IgG for 1 h at room tem-
perature. After washing in PBS, the slides were mounted
and examined using a confocal microscope (LSM 5
EXCITER, Carl Zeiss, Oberkochen, Germany) [18].
Statistic analysis
Experimental data are shown as means ± standard error of
mean (SEM). The unpaired Student’s t-test was used to
analyze the results for statistical significance when only
two conditions were compared. P values below 0.05, 0.01,
or 0.001 were considered significant. The densitometry
analysis of immunoblots, PCR and EMSA was performed
with Quantity One version 4.6.3 (BIO-RAD, Hercules,
C A ) ,n u m b e r sb e l o wb a n d si na l lf i g u r e sa r em e a n
obtained from four independent experiments (n = 4) as
the ratio of band density of each group versus that of total
protein or loading control, and the variable percentile
among four independent experiments was less than 10%.
Histogram for densitometry analysis in the [Ca
2+]i level in
Figures 1A, B and C or Figure 5B was indicated by mean ±




2+]i) levels in co-cultured-astrocytes
Astrocytes secrete many kinds of bioactive substances
including growth factors and cytokines. These secretions
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2+-dependent system, which may play
important roles in the regulation of neuronal and brain
functions [35]. Therefore, we observed the [Ca
2+]i level
in the co-culture of U87 cells and HMC-1 cells or co-
culture of primary astrocytes and bone marrow-derived
mast cells (BMMCs) (hereafter refer to co-cultured-
U87 cells or co-cultured-primary astrocytes; Additional
file 1 Figure S1A). The [Ca
2+]i levels increased in a
time-dependent manner in both the co-cultured-U87
cells (Figure 1A) and co-cultured-primary astrocytes
(Figure 1B). The [Ca
2+]i levels maximized at 20 min in
both the co-cultured-U87 cells and co-cultured-primary
astrocytes.
Effects of anti-CD40 antibody or CD40 siRNA on [Ca
2+]i
levels in co-cultured-astrocytes
Our previous study suggested that astrocytes and mast
cells may cross-talk through CD40-CD40L interaction,
as supported by the report that co-cultured-astrocytes
(U87 cells) enhanced expression of CD40 molecules
[18]. However, CD40L was not detected in co-cultured-
U87 cells, co-cultured HMC-1 cells showed higher levels
of CD40L and similar levels of CD40 molecules com-
pared to the control (Additional file 1 Figure S1B).
Therefore, we observed that whether anti-CD40 anti-
body decreased [Ca
2+]i levels in the co-cultured-U87
cells (Figure 1A) and co-cultured-primary astrocytes
(Figure 1B) in a time-dependent manner, but did not
completely inhibit [Ca
2+]i levels in either co-cultured-
astrocytes. CD40 siRNA, which confirmed the expres-
sion of CD40 after CD40 siRNA transfection (Additional
file 2 Figure S2A), or 8-oxo-dG (8-hydroxydeoxyguano-
sine), which is a Rac1/2 and cdc42 inhibitor [34],
also decreased [Ca
2+]i levels in co-cultured-U87 cells
(Figure 1C).
Effects of anti-CD40 antibody, CD40 siRNA or 8-oxo-dG
on cytokine expressions in co-cultured-U87 cells
We previously reported that cytokine protein and
mRNA expression [IL-1b,I L - 4 ,I L - 5 ,I L - 6 ,I L - 8 ,I L - 9 ,
IL-10, TNF-a, monocyte chemotactic protein-1 (MCP-
1), regulated on activation normal T cell expressed and
secreted (RANTES), interferon-gamma-induced protein-
10 (IP-10), and monokine induced by IFN-gamma
(MIG)] were secreted into the co-cultured media and
expressed in co-cultured-mast cells, respectively [18].
The cytokine mRNAs such as ones for IL-1b,I L - 6 ,
TNF-a, MCP-1, RANTES, and IP-10 were also
increased in both co-cultured-U87 cells and -primary
astrocytes (Additional file 1 Figure S1C). Anti-CD40
antibody, CD40 siRNA or 8-oxo-dG pretreatment
prevented this increase in cytokine mRNA levels in the
co-cultured-U87 cells (Figure 1E).
Effect of anti-CD40 antibody, CD40 siRNA or 8-oxo-dG on
the various signaling molecules in co-cultured-U87 cells
Rho-family GTPases modulate Ca
2+-dependent ATP
release from astrocytes [36]. Similarly, we observed that
Rho-family GTPase (Rac1, Rac2 and cdc42) activities
reached a maximum at 20 min in co-cultured-U87 cells
or -primary astrocytes (Additional file 2 Figure S2B).
Anti-CD40 antibody, CD40 siRNA or 8-oxo-dG blocked
the increase of these Rho family activities in co-cul-
tured-U87 cells (Figure 1D).
Rac1 increases Ca
2+ influx in epithelial cells [37]. We
confirmed cascades of signal pathways in co-cultured-
astrocytes by observing that 8-oxo-dG inhibited [Ca
2+]i
levels (Figure 1C) as well as Rac1/2, cdc42 activation,
but Ca
2+ inhibitor (2-aminoethoxydiphenyl borate, 2-
APB) did not inhibit Rho family activities (Figure 1D).
We also observed that activities of downstream mole-
cules such as PKC isoforms, MAP kinases and transcrip-
tion factors reached a maximum at 30 min, 1 h and 3 h,
respectively, in the co-cultured-U87 cells and -primary
astrocytes (Additional file 2 Figure S2C, D and Figure
3A). However, the activities of other PKC isoforms (δ, ζ
and l) were not affected in either co-cultured-astrocytes
(data not shown). 8-oxo-dG as well as anti-CD40 anti-
body and CD40 siRNA inhibited phosphorylation of
PKC isoforms and MAP kinases (Figure 2A, B), and
activities of transcription factors NF-Ba n dA P - 1
(Figure 2C). Jak inhibitor (AG490) did not inhibit PKC
isoforms (Figure 2A) and weakly inhibited the phos-
phorylation of MAP kinases (Figure 2B). The order of
signal cascades was Rho-family GTPases, [Ca
2+]i,P K C s
and MAP kinases in accordance with time sequence as
reported previously in co-cultured-mast cells [18].
Since CREB-binding protein (CBP) functions as a
co-activator for various transcription factors including
signal transducers and activators of transcription STAT1
on serine 727 (STAT1
727) and NF-B [38], we examined
whether CBP showed STAT1- and NF-B-dependent
transcriptional synergy. CBP expression was increased in
co-cultured-U87 cells and decreased by various inhibi-
tors (Figure 2D). This data demonstrated that CBP was
mediated by Rho-family GTPase/PKCs/NF-Ba n d
STAT
727 pathways.
Phosphorylations of Janus kinase 1 (Jak1) and Jak2 or
expression of STAT1 in co-cultured-U87 cells
Jak/STAT signal pathways play a critical role in the
cytokine-dependent stimulation of astroglial cells [39],
and as presented in Figure 1E, co-cultured-astrocytes
expressed cytokines mRNAs. Therefore, we examined
their signal pathways for cytokines expression. Interest-
ingly, phosphorylation of both Jak1/2 and STAT1 on
tyrosine 701 (STAT1
701)s h o w e dd i p h a s i ci n c r e a s ei n
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Page 6 of 16Figure 1 Activation of astrocytes co-cultured with mast cells. Astrocytes (3 × 10
6 cells) and mast cells (1 × 10
6 cells) were co-cultured in a
3:1 ratio. The anti-CD40 antibody (300 ng/ml), Jak inhibitor (10 μM AG490), 8-oxo-dG (300 μg/ml) or 2-APB (100 μM) was pretreated in astrocytes
1 h, 5, 10 and 10 min, respectively, before co-culture, and CD40 siRNA was transfected as described in “Methods”. Fluro-3 AM (5.0 μM) was
added to co-cultured-U87 cells or -primary astrocytes and incubated for 30 min. The [Ca
2+]i level in U87 cells or in primary astrocytes was
analyzed by confocal laser scanning microscopy. Rho-family GTPases or expressions of cytokine mRNA were determined in protein extracts and
nuclear extracts by GST pull-down assay and RT-PCR, respectively. (A, B) Time course of [Ca
2+]i level in co-cultured-U87 cells or -primary
astrocytes, respectively, and in anti-CD40 antibody pretreatment. (C) The [Ca
2+]i level after pretreatment with anti-CD40 antibody, CD40 siRNA or
other inhibitors. (D) The activation of Rho-family GTPases by various inhibitors. (E) Expressions of cytokine mRNA caused by various inhibitors.
U87 cells, U87 cell culture alone; BAC, primary astrocyte culture alone; Co-culture, U87 cells co-cultured with HMC-1 cells or BAC with BMMCs;
Anti-CD40 Ab, anti-CD40 antibody pretreatment; CD40 siRNA, CD40 siRNA transfected-U87 cells co-cultured with HMC-1 cells; AG490, Jak
inhibitor; 8-oxo-dG, 8-hydroxydeoxyguanosine. *, The numbers below bands are mean values and Figure 1A, B and C are mean ± SEM obtained
from four independent experiments (n = 4) as the ratio bad density of each group versus that of total protein or GAPDH using densitometry
analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus U87 cell or primary astrocyte culture alone.
++, P < 0.01;
+++, P < 0.001 versus co-cultured-
U87 cells or -primary astrocytes.
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Page 7 of 16Figure 2 Effects of inhibitors on activation of signal molecules in co-cultured-U87 cells. Experimental details in co-culture were indicated
in Figure 1. The anti-CD40 antibody (300 ng/ml), Jak inhibitor (10 μM AG490) or 8-oxo-dG (300 μg/ml) was pretreated in astrocytes 1 h, 5 and
10 min, respectively, before co-culture, and CD40 siRNA was transfected, as described in “Methods”. Activities of PKCs, MAP kinases and
transcription factors were determined in protein extracts and nuclear extracts by Western blot and EMSA, respectively. (A, B) Activities of PKC
isoforms and MAP kinases after inhibitor pretreatment. (C, D) Activities of NF-B (upper panel) or AP-1 (lower panel) and expression of CBP after
inhibitor pretreatment. *, Numbers below bands are mean values obtained from four independent experiments (n = 4) as the ratio of band
density of each group versus that of total protein or actin using densitometry analysis.
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Page 8 of 16co-cultured-astrocytes. That is, the phosphorylation of
Jak1/2 and STAT1
701 were initiated at 3 min and
10 min, and reached at a maximum 10 min and 15 min,
respectively. And, their phosphorylation was strongly
induced and maximized at 6 h after co-culture
(Figure 3A, B). However, the phosphorylation of
STAT1
727 only reached a maximum at 3 h in co-cultured-
U87 cells (Figure 3B).
The effect of inhibitors on Jak1/2 and STAT1 in co-
cultured-U87 cells
To confirm the signal cascade downstream of Jak/
STAT1, we used various inhibitors. First, we observed
that phosphorylation of Jak1/2 was inhibited by anti-
CD40 antibody, CD40 siRNA or Rac inhibitor 8-oxo-dG
as well as Jak1/2 inhibitor AG490 (10 μM) (Figure 3C).
The Jak inhibitor (AG490) was not effective on [Ca
2+]i
level (Figure 1C) and small GTPases (Figure 1D).
Anti-CD40 antibody, CD40 siRNA or 8-oxo-dG inhib-




2+ influx inhibitor (2-APB) inhibited STAT1
701
and STAT1
727 (Figure 3D). However, with pretreatment
of these inhibitors, STAT1
727 activity downstream of
Rho-family and Ca
2+ signals was reduced by a much
greater degree compared to STAT1
701 activity. This
phenomenon inferred that STAT
701 is not downstream
of Ca
2+ s i g n a l s ,b u ti ti si n d i r e c t l ye v o k e db yi n h i b i t i n g
the Ca
2+ pathway via Rho-family
A PKCa- and bI-specific inhibitor (5 nM Gö6976) and
non-specific inhibitor (5 nM staurosporine), or all inhi-
bitors of MAP kinases (50 μM PD98059, 10 μM
SP600125, 10 μM SB203580) remarkably inhibited the
phosphorylation of STAT1
727, but weakly inhibited
STAT1
701 activity (Figure 3E, F).
To elucidate the signaling cascades of PKC and MAP
kinase, we used inhibitors of PKCs and MAP kinases,
although the order of their cascades was observed over
the time courses for the above activities (Additional file
2 Figure S2C, D and Figure 3A). These results showed
that MAP kinases are downstream of PKC isoforms
(Additional file 3 Figure S3B, C) as reported previously
in co-cultured-mast cells [18]. Additionally, PKC inhibi-
tors and MAP kinase inhibitors reduced the activities of
transcriptional factors or cytokine expression (Addi-
tional file 4 Figure S4A, B).
Effects of TNF receptor 1 (TNFR1) antibody on activation
of co-cultured-U87 cells
Since various cytokines were secreted in the co-culture
system and Jak/STAT1
701 were activated by diphasic
events, we inferred that cytokines secreted from co-
cultured-astrocytes may re-activate astrocytes. Thus,
we targeted TNF-a which is secreted by both co-
cultured-astrocytes and -mast cells and is also related
to neurodegeneration and chronic inflammation in
astrocytes [40]. First, we observed that TNF-a receptor
1 (TNFR1) expression reached a maximum at 3 h in
the co-cultured-U87 cells (Figure 4A; left-upper panel).
However, this was only weakly enhanced in co-cul-
tured-HMC-1 cells and reached a maximum at 5 h
(Figure 4A; left-lower panel). Receptor expression was
strongly inhibited by anti-CD40 antibody, CD40 siRNA
or 8-oxo-dG in co-cultured-U87 cells, but Jak inhibitor
( A G 4 9 0 )d i dn o tr e d u c e( F i g u r e4 A ;r i g h tp a n e l )
expression.
Anti-TNFR1 antibody (300 ng/ml) pretreatment
suppressed activities of Jak1/2 (Figure 4B) and STAT1
(Figure 4C), and CBP expression (Figure 4D). TNFR1 anti-
body inhibited activity of STAT1
701 downstream of Jak
signal cascades more than that of STAT1
727 (Figure 4C).
Anti-TNFR1 antibody also suppressed expression of IL-1b
and IL-6 mRNA as well as TNF-a mRNA expressed in
co-cultured-U87 cells (Figure 4E). Optimal time (30 min)
and concentration (300 ng/ml) for inhibition by anti-
TNFR1 antibody were determined in the preliminary
experiments (Additional file 5 Figure S5A, B).
Clinical EAE score and co-localization of TNFR1 and
astrocyte surface marker in EAE-induced brain tissues
In our data, EAE score (3.8 ± 0.21) maximized on days
32, and inflammatory cells were remarkably infiltrated
into brain tissues (Additional file 6 Figure S6A). Anti-
CD40 antibody significantly reduced EAE score, but
8-oxodG weakly inhibited. Both treatments reduced
more than additive effect of each inhibitor (Figure 5A).
It has been suggested that TNF-a plays a pivotal role in
the pathogenesis of inflammatory demyelinating disease
in MS [26,41] and EAE models [18,42]. Therefore, we
investigated the expression of TNFR1 in the EAE model
(Figure 5B). In the EAE thalamus co-localized with mast
cells and astrocytes, TNFR1 level was remarkably
enhanced. This enhancement of cytokine receptor was
observed more frequently in astrocytes than in mast
cells. Pre-treatment with anti-CD40 antibody, 8-oxo-dG,
or a combination of both compounds decreased TNFR1
expression (Figure 5B).
Next, we investigated co-localization of TNFR1 and sur-
face molecule of astrocytes or mast cells in the brain of the
EAE model. TNFR1 expression (green) and GFAP (red)
was enhanced in astrocytes in EAE brain tissues. Co-
localization of TNFR1 and GFAP (yellow) was enhanced in
astrocytes double-labeled with GFAP (red) and TNFR1
(green) in the EAE (Figure 5C). In double-labeling with
c-kit (red) and TNFR1 (green) in brain tissues, TNFR1
expression was enhanced in EAE brain tissues, but co-loca-
lization of TNFR1 and c-kit was enhanced weaker than
surface markers of astrocytes (Additional file 6 Figure S6).
Anti-CD40 antibody or 8-oxo-dG reduced expression of
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Page 9 of 16Figure 3 Effects of inhibitors on activation of Jak 1/2 or STAT1 in co-cultured-U87 cells. Experimental details in co-culture were indicated
in Figure 1. The anti-CD40 antibody (300 ng/ml), Jak inhibitor (10 μM AG490), 8-oxo-dG (300 μg/ml), PKC inhibitors (5 nM Gö6976 or
staurosporine) or inhibitors of MAP kinase (50 μM PD98059 for ERK, 10 μM SP600125 for JNK, 10 μM SB203580 for p38) was pretreated in
astrocytes 1 h, 5, 10 or 10 min, respectively, before co-culture, and CD40 siRNA was transfected, as described in “Methods”. Activities of JAKs and
STAT1 were determined in protein extracts by western blot using densitometry analysis. (A, B) Time courses for activities of Jak 1/2 and STAT1
after co-culture. (C, D) Activities of Jak 1/2 and STAT1 after inhibitors pretreatment. (E, F) Phosphorylation of STAT1 after pretreatment with PKC
and MAP kinase inhibitors. *, Numbers below bands are values obtained from four independent experiments (n = 4) as the ratio of band density
of each group versus that of total protein using densitometry analysis.
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Page 10 of 16Figure 4 The effects of anti-TNFR1 antibody on the activation of co-cultured-U87 cells. Experimental details in co-culture were indicated
in Figure 1. The anti-TNFR1 antibody (300 ng/ml) or anti-CD40 antibody (300 ng/ml) was pretreated in astrocytes 30 min and 1 h before co-
culture. Expressions of TNFR1, activities of JAKs, STAT1 and CBP, and expressions of cytokine mRNA were determined in protein extracts and
nuclear extracts by western blot and RT-PCR, respectively. (A) Expression of TNFR1 in co-cultured-U87 (left-upper panel) or -HMC-1 cells (left-
lower panel), and expression of TNFR1 after inhibitor pretreatment (right panel). (B, C) Phosphorylations of Jak1/2 and STAT1 after inhibitor
pretreatment. (D) Expression of CBP after inhibitor pretreatment. (E) Expressions of cytokine mRNA after inhibitor pretreatment. U87 cells, U87
cell culture alone; TNFR1, anti-TNFR1 antibody alone pretreatment in U87 cells; Co-culture, U87 cells co-cultured with HMC-1 cells; aCD40, anti-
CD40 antibody pretreatment; aCD40 + TNFR1, anti-CD40 antibody and anti-TNFR1 antibody pretreatment before co-culture. *, Numbers below
bands are values obtained from four independent experiments (n = 4) as the ratio of band density of each group versus those of total protein,
actin or GAPDH using densitometry analysis.
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Page 11 of 16Figure 5 Clinical score and co-localization of TNFR1 in EAE-induced mouse brain. EAE mouse model was immunized with MOG and CFA,
and scored daily as described in “Methods”. Mice received anti-CD40 antibody (1 mg/kg), 8-oxo-dG (60 mg/kg) or a combination of anti-CD 40
antibody and 8-oxo-dG, respectively, with i.p. injection for 5 days after MOG injection. After animal sacrifice at day 32 (EAE score, 3.8 ± 0.21), brains
were removed and preserved in 10% neutral buffered formalin. Expressions of TNFR1 were determined in protein extracts by western blot, and
co-localization was determined by double staining for TNFR1 (green) and GFAP (red). (A) EAE score after pretreatment with inhibitors Data are mean ±
SEM (n = 8). (B) Expression of TNFR1 (n = 4). Histogram for densitometry analysis was indicated by mean ± SEM (n = 4) obtained from four
independent experiments. (C) Co-localization of TNFR1 and astrocytes after pretreatment with inhibitors (n = 4). The image depicted one of
representative results after four independent experiments were determined. TNFR1, TNF-a receptor 1; aCD40, anti-CD40 antibody; 8-oxo-dG,
8-hydroxydexoyquanosine; both, a combination of anti-CD40 antibody and 8-oxo-dG. Bar in control group indicates 100 μm.
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Page 12 of 16TNFR1 in astrocytes in the brain of the EAE model, and a
combination of both compounds inhibited TNFR1 expres-
sion more than use of each agent alone.
We produced schematic diagrams showing signaling
pathways in the activation of astrocytes through CD40-
CD40L interaction in co-culture with mast cells (Figure 6).
This diagram suggest that activation of astrocytes caused
by co-culturing with mast cells through CD40-CD40 inter-
action mainly induces production of cytokines and chemo-
kines via Rho-family GTPases/Ca
2+-dependent PKC
isoforms, MAP kinases, NF-B and STAT1
727. These cyto-
kines subsequently re-activate astrocytes, and enhance the





This study demonstrated that astrocytes are activated by
interaction of CD40-CD40L in a co-culture system with
mast cells. The activated astrocytes induced production




727 signal pathways, which in turn
re-activate astrocytes via the Jak/STAT1
701 signal path-
ways. Anti-CD40 antibody or CD40 siRNA inhibited all
signal cascades via small GTPases, and anti-CD40 anti-
body or 8-oxodG reduced the EAE score and TNFR1
expression in EAE brain. Therefore, our data suggest
that astrocytes activated by cell-to-cell contact, particu-
larly with mast cells, may exacerbate the development of
neurodegenerative disease including demyelization, such
as MS, due to enhancement of cytokine receptor expres-
sion on astrocytes caused by inflammatory cytokine
secretion as well as interaction of CD40 with CD40L in
vitro and in mouse EAE model.
Mast cells accumulate in MS plaques [6,7] and in EAE
brain [18,19,21]. Mast cells are activated by CD40-CD40L
interaction in a co-culture with astrocytes, and both cells
surface markers are enhanced and co-localized in EAE
brain tissues [18], although it has been reported that
mast cells are dispensable for the development of EAE
[20]. Thus, the interaction between CD40 and CD40L
plays an important role in signal transduction pathways
in humoral and cell-mediated immune responses. CD40-
CD40L interaction produces high levels of proinflamma-
tory cytokines in immune cells of the CNS, including
microglia and astrocytes [43,44]. During brain inflamma-
tion, astrocytes also are producers of a variety of cyto-
kines including IL-1, IL-6, TNF-a, IL-10 and TGF-b,a n d
chemokines attracting T cells within the CNS [23,44].
A variety of exocytotic mediators released from astrocytes
influences neuronal development, function and plasticity
[45]. Our data showed that these released cytokines are
produced in astrocytes activated through CD40-CD40L
interaction in the co-culture system (Figure 1E), as
demonstrated by other laboratories that the appearance
of CD40 in the CNS correlates with the expressions of
inflammatory cytokines [23,44]. However, secretory path-
ways and the involved molecular mechanisms in astro-
cytes are poorly understood.
Activation of astrocytes, which provides support for neu-
ronal function in the healthy and inflamed CNS [2], is
usually manifested as a rise of intracellular Ca
2+ ([Ca
2+]i)
level due to release of Ca
2+ from internal stores as well as
Ca
2+ uptake from the extracellular space [45,46]. Thus, in
order to clarify signal pathways for the production of cyto-
kines induced in co-cultured-astrocytes, we first confirmed
that a rise of [Ca
2+]i level is induced through interaction of
CD40 with CD40L in adjacent cells (Figure 1A, B).
Rho-family GTPases activate intracellular kinase cas-
cades to modulate gene transcription, and participate in
regulated secretory pathways [47], while Rac1 contributes
to activation of STAT1 in astrocytes [48]. Our data sug-
gest that Rho-family GTPases up-regulated downstream
[Ca
2+]i levels in co-cultured-astrocytes as Rac inhibitor
(8-oxo-dG) reduced [Ca
2+]i levels (Figure 1C), but the
[Ca
2+]i inhibitor (2-APB) did not inhibit Rac-family activ-
ity in co-cultured-astrocytes (Figure 1D).
Ca
2+-dependent PKC and MAP kinase are the main
signaling pathways involved in the synthesis and secre-
tion of mediators [49]. MAP kinase components, such as
Figure 6 Schematic diagram showing signaling pathways in
co-cultured-astrocytes. The data suggest that activation of
astrocytes caused by co-culturing with mast cells through CD40-
CD40 interaction mainly induces production of cytokines and
chemokines via Rho-family GTPases/Ca
2+-dependent PKC isoforms,
MAP kinases, NF-B and STAT1
727. These cytokines subsequently re-
activate astrocytes, and enhance the production of a variety of
cytokines via Jak/STAT1
701 or STAT1
727/CBP pathways. TNFR1, TNF-a
receptor 1; CD154, CD40 ligand. Broken lines show parts of the
pathways requiring further study.
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Page 13 of 16ERK1/2, have an important role in astrocyte activation
[23,50]. Astroglial reactivity, which is associated with the
production of NF-B-dependent proinflammatory mole-
cules, is also an important component of the pathophy-
siology of chronic neurological disorders [22,24].
Additionally, phosphorylation of STAT1 on serine 727
(STAT
727) independent of tyrosine phosphorylation
(STAT
701), which is activated downstream of PKCs and
MAP kinases, is required to enhance transcriptional
activity in various cells [48]. Therefore, our data inferred
that astrocytes can be directly activated by CD40-CD40L
interaction in co-culture, and that CD40-CD40L interac-
tion mainly mediates signal cascades via Rho-family
GTPases (Rac1/2, cdc42), [Ca
2+]i levels, PKCs (a, bI, bII),
MAP kinases, transcription factors (NF-B or AP-1) and
STAT1
727 (Figure 1A, B, C, D). This is supported by our
data showing that phosphorylation of STAT1
727 func-
tioned as a downstream regulator of PKCs (Figure 3C)
and MAP kinases, and that the phosphorylation of
STAT1
727 was inhibited by Rac, Ca
2+, PKCs, MAP kinase
inhibitors; however, Rho-family GTPases, [Ca
2+]i,a n d
PKCs were not inhibited by Jak inhibitor (Figures 1C, D).
Pretreatment with anti-CD40 antibody or CD40
siRNA significantly attenuated cytokine production and
activation of signal molecules in the co-culture system,
but did not completely inhibit. This implies that inflam-
matory cytokines secreted by cell-to-cell interaction of
both cell surfaces may re-activate each other or that
other signal pathways maybe exist. There are also
reports that Jak/STAT
701 signaling pathway is involved
in early events of cytokine stimulation in astrocytes [39],
and that various cytokines and their receptors are
expressed via the Jak/STAT1
701 pathway in brain section
of patients with MS [51]. Therefore, we focused on the
Jak/STAT
701 cytokine signaling pathway. Jak/STAT1
701
was not involved in Rac/Ca
2+/PKCs pathways (Figures 1C,
D and 2A). Activities of Jak/STAT
701 showed diphasic
responses (Figure 3A, B). It can be inferred that Jak/
STAT1
701, which is weakly activated early (peak activity at
3 and 10 min, respectively) after co-culturing, is induced
by interaction of CD40-CD40L. And, our data also infer
that Jak/STAT
701, which is strongly activated late (peak
activity at 6 h) after co-culturing, is evoked by cytokines
secreted via the Rho-family pathway. Therefore, our data
suggest that cytokines produced in co-cultured-astrocytes
are mainly induced by signaling via Ca
2+/PKCs/MAP
kinases/STAT1
727 downstream of Rho-family GTPases,
and cytokine-induced astrocyte re-activation leads to
further cytokine production via the Jak/STAT1
701 path-
way. Evidence of this event is supported by our data that
anti-TNFR1 antibody as well as anti-CD40 antibody sup-
pressed activation of Jak/STAT1
701 and induction of cyto-
kine mRNAs in co-cultured-astrocytes. This indicates that
TNF-a bound to TNFR1 re-activates astrocytes via the
Jak/STAT
701 pathway (Figure 4). Also, the reason why we
chose TNF-a among the various cytokines secreted by
co-cultured-astrocytes is that the TNF-a produced by
astrocytes plays multiple roles in the development of neu-
rological disorders [40] including MS [26] and EAE mod-
els [52,53] and the induction of other inflammatory
cytokines, such as IL-1b and IL-6 etc. and chemokines
[42]. Furthermore, overexpression of IL-1b and IL-6 in the
CNS is also correlated with chronic active plaques in MS
[54] and the development of EAE [27]. In showing that
expression of IL-1b and IL-6 mRNA was inhibited by
TNFR1 antibody (Figure 4E), our data are consistent with
reports from other laboratories [42,55]. MCP-1 and IP-10
expressed in co-cultured-astrocytes also recruit leukocytes
and provoke more inflammation [56].
STAT1 and NF-B, which are integral transcription
factors functioning in the regulation of genes involved
in immune and inflammatory reactions, were shown to
bind to the N-terminal and the C-terminal regions of
CBP [57,58]. In the present study, the increased CBP
expression was inhibited by various inhibitors of CD40,
Rac, PKC, Jak and TNFR1 (Figure 2D). These data sug-
gest that CBP is activated by two pathways (Jak/
STAT
701 and Rho-family GTPasea/NF-B-STAT1
727).
We previously reported that mast cell population and
co-localization of astrocytes and mast cells were increased
in the thalamus of the EAE model [18]. Now, we demon-
strated that TNFR1 expression was enhanced in co-cul-
tured-astrocytes and thalamus of EAE-induced brain
tissues. Co-localization of TNFR1 and astrocyte surface
marker was also enhanced in the EAE-induced brain, and
their co-localization and EAE score were reduced by anti-
CD40 antibody or 8-oxo-dG administration (Figure 5). MS
is a chronic and demyelinating disease affecting the white
matter of the CNS, and an accumulation of mast cells in
MS plaque was mainly increased in the demyelinated area
i.e. the white matter [10]. However, the reason why we
observed TNFR1 expression in thalamus is that mast cells
are abundant in the thalamus, and considerable numbers
of them are in the hypothalamus and median eminence in
rat EAE model [59] and enhanced in thalamus and
meninges of GFAP-IL3 mice in CNS demyelination, and
that this study focused on the interaction of astrocytes and
mast cells [60]. Therefore, we can infer that alteration of
TNFR1 expression may be related to clinical manifestation
of EAE, thus anti-CD40 antibody may attenuate the devel-
opment of EAE in mice. That is, the data suggest that
astrocytes and mast cells may directly interact in close
proximity in the thalamus and produce inflammatory
cytokines, and that EAE-related-cytokines secreted by cell-
to-cell interaction re-activate each other, particularly
astrocytes, and then enhance the expression of cytokine
receptor and release more mediators including cytokines
that may contribute to exacerbating the development of
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Therefore, it seems to us that a combination of anti-CD40
antibody and TNFR1 blockers may need for neurodegen-
erative disease therapy like MS. However, further study is
needed to fully understand the role of CD40-CD40L inter-
action in the EAE model and their potential as therapeutic
targets.
Conclusions
The present study demonstrated that astrocytes acti-
vated through CD40-CD40L interaction in a mast cell
co-culture system produce pro-inflammatory cytokines
through Rho-family GTPases/Ca
2+ mobilization/PKCs/
MAP kinases and NF-B or STAT1
727 pathways, and
the produced cytokines subsequently re-activate
astrocytes via Jak/STAT1
701. This study suggests that
cell-to-cell contact between both types of cells is bi-
directionally activated in vitro and in EAE model, and
that both types of activated cells may initiate develop-
ment of neurodegenerative diseases through various
mediators. Furthermore, our data suggest that the pro-
inflammatory mediators produced by interaction of both
cell types may potentially exacerbate the development of
demyelination in disease like MS, and this interaction
may be potential therapeutic targets.
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